303 results about "B-Cell Epitopes" patented technology

The present invention relates to a bovine VDJ cassette (BF1H1) that provides the novel ability to develop chimeric immunoglobulin molecule capable of incorporating both linear T cell epitope(s) (CDR1H and CDR2H) as well as conformational B cell epitope(s) (exceptionally long CDR3H). Further, multiple epitopes can be incorporated for development of multivalent vaccine by replacing at least a portion of an immunoglobulin molecule with the desired epitope such that functional ability of both epitope(s) and parent VDJ rearrangement is retained. The antigenized immunoglobulin incorporating both T and B epitopes of interest is especially useful for development of oral vaccines for use in humans apart from other species including cattle. The long CDR3H in BF1H1 VDJ rearrangement originates from long germline D-genes. The novel bovine germline D-genes provide unique molecular genetic marker for sustaining the D-gene pool in cattle essential for immunocompetence via selective breeding. D-gene specific DNA probe permits typing and selection of breeding cattle stock for maximum gemline D gene pool for better health and disease prevention. The bovine D-genes are unique to cattle and, therefore, provide sensitive and specific forensic analytical tool using molecular biology techniques to determine tissues suspected of bovine origin.

The invention discloses a method for detecting the specific antibody of classical swine fever virus and a special ELISA kit thereof. The kit includes a classical swine fever virus antigen and an enzyme-labeled classical swine fever virus single-epitope specific antibody; the said swine fever virus antigen is a polypeptide containing one or more than one amino acid residue sequence described in sequence 1. The detection reagent of the classical swine fever virus specific antibody of the present invention can carry out effective detection to the classical swine fever virus specific antibody by solid-phase antigen competition ELISA (blocking method); The B cell epitope ensures the differential diagnosis, and the high degree of conservation of the epitope among various strains ensures the specificity of detection.

The invention discloses a foot-and-mouth disease genetic engineering mixed epitope vaccine and a preparation method thereof. The vaccine consists of the following four parts: a serial B cell epitope recombinant protein BI consisting of main neutralizing epitops of O-type foot-and-mouth disease viruses in Cathay, Transasia and Mya 98 pedigrees with a gene sequence of SEQ ID NO:1 and an amino acid sequence of SEQ ID NO:2, a T-cell epitope recombinant protein TI consisting of serial connection of universal T-cell epitope and a plurality of foot-and-mouth disease virus specific T-cell epitopes with a gene sequence of SEQ ID NO:3 and an amino acid sequence of SEQ ID NO:4, Toll-like receptor 3 agonist-polyinosinic acid-polycytidysic acid and/or Toll-like receptor7/8 agonist-R848 serving as immunopotentiator, and 201 oil adjuvant. When being used for immunizing a pig, the BI and TI mixed epitope vaccine prepared by utilizing the method can produce a protective immunization effect the same as or better than that of an inactivated influenza virus Vaccines, and has a cross protection effect to viruses of the three pedigrees, so that the vaccine is a novel immune-enhanced O-type foot-and-mouth genetic engineering mixed epitope vaccine.

The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the precursor or mature protein are self molecules. The chimeric peptide or peptides have an end-specific B cell epitope from a naturally-occurring internal peptide cleavage product of a precursor or mature protein, as a free N- or C-terminus, fused with or without spacer residues to a T helper cell epitope derived from a living source different from that of the internal peptide cleavage product.

The invention belongs to the field of medicine, particularly relates to a diagnostic technique of heart failure, and specifically relates to a B cell epitope peptide segment of amino-terminal pro-brain natriuretic peptide. An amino acid sequence is shown in SEQ ID NO:4 or SEQ ID NO:5. The prepared specific antibody can be used as a diagnostic reagent of heart failure. The amino-terminal pro-brain natriuretic peptide prepared by the invention is high-purity monomer recombinant protein of the amino-terminal pro-brain natriuretic peptide. The protein can be used for immunogen and screening collagen prepared from an antibody, and can be simultaneously used as a calibrator when the amino-terminal pro-brain natriuretic peptide is built to carry out quantitative detection. A monoclonal antibody prepared by immune mice at the B cell epitope peptide segment of the amino-terminal pro-brain natriuretic peptide has the advantages of high purity (SDS-PAGE detection purity greater than 96%), high valence (the valence of ELISA up to 1:512000), good specificity, mass preparation, and the like.

The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.

The invention discloses a set of epitope polypeptides, particularly relates to a neutralizing B cell epitope sequence of encephalitis B virus E protein, and further discloses application of controlling and diagnosing encephalitis B virus by these epitopes. The amino acid sequences of the epitope polypeptides in the invention are respectively any amino acid sequence of SEQ ID NO: 64, SEQ ID NO: 79, SEQ ID NO: 95, SEQ ID NO: 108, SEQ ID NO: 124 and SEQ ID NO: 139. After the epitope polypeptides in the invention are coupled or fused with carrier proteins to be expressed as immunogenic or vaccine immuno animal organism, neutralizing antibodies aiming at JEV can be generated, and the JEV can be neutralized in vivo or in vitro so as to prevent virus from infecting animal organism. The epitope polypeptides in the invention or the junctional complex thereof can be used as reagents for detecting encephalitis B virus antibodies or encephalitis B virus polypeptide antibodies.

A method for screening wheat varieties with low celiac sprue toxicity based on T cell epitopes comprises the following steps: separating and extracting wheat gluten protein in two steps, performing SDS-PAGE electrophoresis combined with PageBlue TM staining method to identify the gluten protein, detecting celiac sprue T cell epitopes caused by the gluten protein through immunoblotting and other steps. According to the invention, T cell epitopes-based screening method is adopted to screen out the wheat varieties with low celiac sprue toxicity, so that safe and reliable low gluten food can be supplied for celiac sprue patients from the origin of raw materials, and the safety risk of the celiac sprue patients is reduced.

The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope.

The invention discloses the sequence of a specific B cell epitope polypeptide of an NS1 protein of encephalitis B virus and the use of the epitope polypeptide in the diagnosis of encephalitis B virus and a screening method of specific B cell epitope polypeptide of NS1 protein of encephalitis B virus, and belongs to the field of molecular immunology. The amino sequence of the epitope polypeptide is represented by SEQ ID No.1 or SEQ ID No.2. The specific B cell epitope synthetic polypeptide of the JEV NS1 protein, the coupling antigen of the synthetic epitope polypeptide and the epitope fusion expression protein can be used for specifically detecting a JEV NS1 protein antibody generated in body which is immunized and infected. The epitope polypeptide can be used for diagnosis of JEV infection, evaluation on immunity effect and identification and diagnosis of immunity of inactivated vaccine and natural infection.

The invention relates to a porcine circovirus II-type (PCV2) epitope peptide vaccine and a preparation method of the vaccine. The vaccine contains three b cell epitopes, the lysine of the vaccine is four-branch peptide with the same core matrix structure epitope monomer and is connected with a general T ancillary cell (Th) epitope in series, and the vaccine has the molecular weight of 13kDa; the epitope peptide is named PCV CP98-156-228; after being vaccinated, a mice has stronger immune response, and a high potency virus neutralizing antibody can be generated. The epitope peptide vaccine has the advantages of being low in price, safe, high in specificity and easy to store and apply, and plays an important role in preventing and controlling the porcine circovirus disease. The PCV2 epitope peptide vaccine is prepared by four steps including predicting and screening epitope peptide, designing the epitope peptide vaccine, synthesizing, purifying and authenticating the epitope peptide as well as preparing the epitope peptide vaccine; the method is easy in raw material obtaining, lower in cost and easy to control, and has better operability, thus being suitable for being popularized and applied.

The present invention relates to biomedicine engineering technology, and is the gene cloning of polyepitope antigen of hepatitis C virus hcvme and the coded polyepitope antigen HCVME. The hcvme includes 9 epitope genes of HVR1 simulating B cell and 4 epitope genes of T cell in E2 region of HCV genome, and the 4 epitope genes of T cell includes 2 of conservative CTL epitope in region C, 1 of conservative CTL epitope in region NS3 and 1 of conservative Th epitope in region NS3. Serial tests show that hcvme has high cross reaction with karyogamy expressed product GST-HCVME of gst gene and positive hepatitis C antibody serum, and the GST-HCVME immunized male rabbit serum has high distinction frequency on natural HVR1 synthetic peptide. Therefore, hcvme and its expressing product HCVME may be used in preparing nucleic acid vaccine and polypeptide vaccine for hepatitis C and the test reagent for HCV antigen and antibody.

The invention provides O-type aftosa synthetic peptide vaccine, and in particular relates to polypeptide or polypeptide polymer thereof used in the vaccine as well as the vaccine containing the polypeptide or the polypeptide polymer thereof and a preparation method thereof. The polypeptide has amino acid sequences shown in SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3. The O-type aftosa synthetic peptide vaccine carries out chemical synthesis of potential antigen site peptide segments by carrying out sequencing of domestic aftosa epidemic strains to study the variation of the main antigen sites ofaftosa and combining with computer assistant to carry out antigen site analytical prediction. Candidate polypeptide antigens are screened out by carrying out large numbers of animal experiments and aftosa virus antigen sites are optimized according to the screening result; and T cell epitope and B cell epitope are effectively combined to improve the immune effects of the polypeptide antigens. TheO-type aftosa synthetic peptide vaccine can effectively cope with the antigen variation of aftosa virus and has ideal biosafety and easy large-scale synthesis, thereby having a good application prospect.

The invention relates to an epitope peptide H362 of an HN protein in PPRV, and determination, a preparation method and application thereof. The amino acid sequence of the epitope peptide is H362: <362>EANWVVPSTDVRDL<375>. The invention detects reactogenicity of a monoclonal antibody and PPRV and specificity of the monoclonal antibody; according to detection results, the monoclonal antibody has good reactogenicity to rPPRV-HN-F protein; immunoinformatic technology is cooperatively used for predicating the B cell epitope of the HN protein; an aminated ELISA plate is employed for detecting candidate epitopes and the monoclonal antibody 10E3, and the epitope peptide H362 corresponding to 10E3 is determined; and determination of the epitope peptide lays a theoretical foundation for preparation of epitope vaccine antigens and diagnostic reagent antigens for PPRV.

A SARS-Cov gene vaccine based on epitope is configured from the carrier which is a plasmid able to be used for human body and the target antigen which is several B cell epitopes in the extrinsic B protein antigen of human SARS coronavirus through codon optimizing and genetic engineering. Its preparing process is also disclosed.

The invention provides three Th cell epitope peptide and code DNA of pylorus spirillum urease B subunit, also providing a bacterin of B cell epitope which contains the triepitope peptide and an additional urease B subunit. Among them, the epitope peptide is the polypeptide which has one of the amino acid residue sequences as follows: 1) hasing amino acid sequence of sequence 2, sequence3 and sequence 7 in sequence table; 2) replacing, deleting or appending the amino acid sequence of sequence 2, sequence3 and sequence 7 in sequence table by one or several amino acid residue to form derivanting polypeptide. The coded DNA is one of the following sequences: 1) hasing the ribonucleotide sequence of sequence 8, sequence 9 and sequence sequence 10 table. 2) Hasing the ribonucleotide sequence of same coded product with sequence 8, sequence 9 and sequence10 in sequence table. The epitope vaccine which contains the polypeptide of this invention has the protein vaccine of amino acid sequence in sequence 12 of sequence table. The vaccine or medication which is made by using the polypeptide of the invention as active component can clean out the infection caused by pylorus spirillum and has wide application prospect in medical realm.

The invention belongs to the pharmaceutical biotechnology field, and relates to enterohemorrhagic E.coli O157:H7 Shiga toxin IIB epitope peptide and the application thereof. Four preferred polypeptides are derived from B-cell epitope of the subunit (Stx2A1) of EHEC O157:H7 Shiga toxin IIB epitope peptide. The product can be applied for preparing pharmaceuticals for the diagnosis and treatment of EHEC O157 infection and complications thereof.

The invention belongs to the medical field and particularly relates to an acute kidney injury diagnosis technology, a B cell epitope peptide of human NGAL (Neutrophil Gelatinase Associated Lipocalin) and a hybridoma cell prepared by same, and an application of the B cell epitope peptide and a specific antibody thereof and an immune complex of the specific antibody in preparing diagnostic reagent for acute kidney injury. The B cell epitope peptide prepared by the invention immunizes a monoclonal antibody prepared by adopting a rat and has the advantages of high purity (The SDS (Sodium Dodecyl Sulfate)-PAGE (PolyAcrylamide Gel Electrophoresi) detection purity is more than 96 percent), high valence (the ELISA (Enzyme-Linked Immuno Sorbent Assay) valence reaches 1:256000), good specificity, mass preparation and the like; and through the monoclonal antibody and a polyclonal antibody prepared by the B cell epitope peptide, the B cell epitope peptide can be used for detecting the content of the NGAL in the urine of a patient, for example, by adopting a double antibody sandwich ELISA reaction mode, a double antibody sandwich structure formed by an enzyme labeled human anti-NGAL monoclonal antibody, an enzyme labeled plate package anti-NGAL polyclonal antibody and a measured sample NGAL antigen is detected.

The invention discloses a monoclonal antibody BTV8-VP2-3E11 resistant to bluetongue virus 8 type (BTV8) VP2 protein, B-cell epitope peptide identified thereby and application, and belongs to the field of BTV8 control. A selected hybridoma cell strain capable of stably secreting a BTV8-VP2 protein resistant monoclonal antibody is stored with a microbial preservation number of CGMCC (China General Microbiological Culture Collection Center) No.7004. The experiment results show that the monoclonal antibody BTV8-VP2-3E11 secreted by the hybridoma cell strain can perform idiosyncratic reaction with the BTV8-VP2 protein but not reacts with the VP2 proteins of other serum types. The monoclonal antibody BTV8-VP2-3E11 and the BTV8-VP2 protein virus specific conserved B cell epitope peptide identified by the a monoclonal antibody can be prepared into an agent used for diagnosing BTV8 infection, thus laying a good foundation for creating serology differential diagnosis methods for BTV8 and other types of serum.

The invention belongs to the field of immunology in medicines and particularly relates to application of a B cell epitope peptide of a human PCT (Procalcitonin) and a monoclonal antibody of the B cell epitope peptide. The epitope peptide is shown as SEQ ID NO:3 and can be used for preparing a hybridoma cell and secreting a corresponding monoclonal antibody. The monoclonal antibody can be used for preparing a diagnostic reagent for detecting the procalcitonin and has the advantages of purity as high as 98 percent, valence as high as 1:512000, favorable specificity, capability of being prepared in a large batch and the like. The monoclonal antibody and a polyclonal antibody which are prepared by the invention can be used for detecting the content of the PCT in the blood of a patient, for example, a double antibody sandwich ELISA (Enzyme-Linked Immuno Sorbent Assay) reaction mode, namely enzyme-labelled anti-human PCT antibody and an elisa plate to used to coat an anti-PCT polyclonal antibody and a measured sample PCT antigen to form a double antibody sandwich structure for measuring.